Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Paraldehyde 100% solution for injection 5ml ampoules
0408020Q0AAACAC
|
Paraldehyde | Paraldehyde | Central Nervous System | No data available |
|
Paraldehyde 50% in Arachis oil rectal solution
0408020Q0AAAHAH
|
Paraldehyde | Paraldehyde | Central Nervous System | No data available |
|
Paraldehyde 50% in Sunflower oil rectal solution
0408020Q0AAAIAI
|
Paraldehyde | Paraldehyde | Central Nervous System | No data available |
|
Paraldehyde 5g/5ml solution for injection vials
0408020Q0AAAKAK
|
Paraldehyde | Paraldehyde | Central Nervous System | No data available |
|
Paramed Cold Relief capsules
0407010X0CPABAF
|
Galpharm (Paracetamol combined) | Paracetamol combined preparations | Central Nervous System | No data available |
|
Paramed Extra Power Pain Control tablets
0407010W0BLAAA0
|
Galpharm (Aspirin combined) | Aspirin combined preparations | Central Nervous System | No data available |
|
Paramed Max Strength Cold and Flu Relief oral powder sachets
0407010ABBGABAB
|
Galpharm (Paracetamol/phenylephrine hydrochloride) | Paracetamol and phenylephrine hydrochloride | Central Nervous System | No data available |
|
Paramed Paracetamol 500mg capsules
0407010H0CPABAA
|
Galpharm (Paracetamol) | Paracetamol | Central Nervous System | No data available |
|
Paramol soluble tablets
0407010N0BHACAK
|
Paramol | Co-dydramol (Dihydrocodeine/paracetamol) | Central Nervous System | No data available |
|
Paramol tablets
0407010N0BHABAJ
|
Paramol | Co-dydramol (Dihydrocodeine/paracetamol) | Central Nervous System | No data available |
|
Parasolve Extra 500mg/65mg effervescent tablets
0407010U0BJAAAC
|
Parasolve Ex | Paracetamol and caffeine | Central Nervous System | No data available |
|
Paroxetine 20mg/5ml oral liquid
0403030P0AAADAD
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | No data available |
|
Paroxetine 30mg/5ml oral liquid
0403030P0AAAEAE
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | No data available |
|
Pentazocine 30mg/1ml solution for injection ampoules
0407020U0AAAAAA
|
Pentazocine lactate | Pentazocine lactate | Central Nervous System | No data available |
|
Pentazocine 50mg suppositories
0407020U0AAABAB
|
Pentazocine lactate | Pentazocine lactate | Central Nervous System | No data available |
|
Pentazocine 60mg/2ml solution for injection ampoules
0407020U0AAACAC
|
Pentazocine lactate | Pentazocine lactate | Central Nervous System | No data available |
|
PEP tablets
0404000D0BEAAAE
|
PEP | Caffeine | Central Nervous System | No data available |
|
Perampanel 2mg/5ml oral suspension
0408010AKAAAKAK
|
Perampanel | Perampanel | Central Nervous System | No data available |
|
Perampanel 4mg/5ml oral suspension
0408010AKAAAGAG
|
Perampanel | Perampanel | Central Nervous System | No data available |
|
Perampanel 5mg/5ml oral suspension
0408010AKAAAIAI
|
Perampanel | Perampanel | Central Nervous System | No data available |
|
Perampanel 6mg/5ml oral suspension
0408010AKAAAHAH
|
Perampanel | Perampanel | Central Nervous System | No data available |
|
Perfalgan 1g/100ml solution for infusion vials
0407010H0CMAADI
|
Perfalgan | Paracetamol | Central Nervous System | No data available |
|
Perfalgan 500mg/50ml solution for infusion vials
0407010H0CMABDK
|
Perfalgan | Paracetamol | Central Nervous System | No data available |
|
Pergolide 1mg tablets
0409010P0AAACAC
|
Pergolide mesilate | Pergolide mesilate | Central Nervous System | No data available |
|
Pergolide 250microgram tab and Pergolide 50microgram tab
0409010P0AAAEAE
|
Pergolide mesilate | Pergolide mesilate | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.